Proteasome Inhibition May Increase Alectinib Efficacy in ALK/TP53-Mutated NSCLC
Investigators studied genetic alterations related to ALK-TKI resistance in NSCLC and explored strategies to overcome resistance in preclinical models.
Investigators studied genetic alterations related to ALK-TKI resistance in NSCLC and explored strategies to overcome resistance in preclinical models.
This study tested the efficacy of singular and combined treatment modalities on survival in patients with inoperable, locally advanced non-small cell lung cancer (≥70 years).
A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.
The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.
Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.
Investigators performed post hoc subgroup analyses by age in patients with relapsed/refractory indolent lymphoma from the MAGNIFY study.
Patients with AML or MDS were significantly more likely to die from COVID-19 vs other HMs. Most treatments did not improve survival outcomes — except corticosteroids.
The limited data underscore “a potential role for passive immunity in this disease,” according to the presenting researcher.
Convalescent plasma therapy may “potentiate the increased thrombotic risk and endotheliopathy” thought to contribute to disease pathophysiology in COVID-19.
CAR-T therapy demonstrated promising antitumor activity with low rates of grade 3 or higher CRS and neurotoxicity among patients with MCL.